Results 201 to 210 of about 181,641 (286)

Sex differences in cardiovascular‑kidney‑metabolic syndrome: From pathogenesis to treatment response (Review). [PDF]

Int J Mol Med
Fan Y, Hu H, Cheng J.
europepmc   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

Angiotensin II type 1 receptor (AGTR1) [PDF]

Science-Business eXchange, 2011
openaire   +3 more sources

Association Analysis of the <i>AGTR2:</i>rs1403543 Polymorphism with Newborn Kidney Size. [PDF]

Genes (Basel)
Miler K, Gorący I, Łoniewska B, Lewandowska K, Lica-Miler M, Rychel M, Ciechanowicz A.   +6 more
europepmc   +1 more source

A New Paradigm: 46 Structural Cell Types Function as Environment‐Supporting Innate Immune Cells, With Endothelial and Vascular Smooth Muscle Cells as Key Prototypes

iNew Medicine, EarlyView.
ABSTRACT The scope, organization, and biological significance of innate immune functions across structural cell types remain poorly defined. To address these fundamental knowledge gaps, we analyzed experimental data of transcriptomes generated by our group and others.
Juanjuan Liu, Gayani K. Nanayakkara, Yifan Lu, Fatma Saaoud, Keman Xu, Ying Shao, Bo Yuan, Shih‐Yu Hung, Haiyan Xiang, Xianwei Wang, Sadia Mohsin, Sheng Wu, Xiaolei Liu, Juncheng Wei, Zhengjie Zhou, Beata Kosmider, Mingui Fu, Laisel Martinez, Roberto Vazquez‐Padron, Wenhui Hu, Shuping Ge, Hong Wang, Xiaofeng Yang   +22 more
wiley   +1 more source

Secondary data analysis of Adverse Drug Reactions reported by healthcare professionals and patients: interventions to manage ADRs of ACE inhibitors and ARBs. [PDF]

Eur J Clin Pharmacol
Spronk SH, Nielen JTH, Heier L, Jessurun N, Kant A, Karapinar-Çarkit F.   +5 more
europepmc   +1 more source

A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside

Interdisciplinary Medicine, EarlyView.
This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione, Ana Talamillo, Juan M. Falcón‐Pérez   +2 more
wiley   +1 more source

Validation of six commercially available angiotensin II type 1 receptor antibodies

Acta Biochimica et Biophysica Sinica
Li Bingjie, Zhang Xi, Sun Fei, Zhang Xingzhong, Liu Huirong, Zhang Suli   +5 more
doaj   +1 more source

Incidence of Hypotension and Clinical Characteristics After the Introduction of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Acute Decompensated Heart Failure: Effects on Cardiac Rehabilitation. [PDF]

Circ Rep
Ando K, Obata K, Fuke S, Matsuzawa R, Tamaki A.   +4 more
europepmc   +1 more source

The Effects of Angiotensin Receptor Neprilysin Inhibitor on Endoplasmic Reticulum Stress in Doxorubicin‐Mediated Cardiomyopathy‐Associated Heart Failure Model in Rats

Journal of Applied Toxicology, EarlyView.
ABSTRACT One of the most serious complications associated with the use of the chemotherapeutic agent doxorubicin (DOX) is cardiomyopathy. Although cardioprotective drugs such as angiotensin receptor‐neprilysin inhibitors (ARNI) are used to prevent cardiomyopathy in DOX patients, no studies have reported the relationship between ARNI and endoplasmic ...
Mert Unvan, Meryem İlkay Karagül, Hatice Oruç Demirbağ, Ebru Balli   +3 more
wiley   +1 more source